---
schema_version: "secwatch.filing_event.v1"
accession: "0001005286-25-000133"
form_type: "8-K"
ticker: "LFCR"
cik: "0001005286"
company_name: "LIFECORE BIOMEDICAL, INC. DE"
filed_at: "2025-09-26T23:59:59+00:00"
generated_at: "2026-05-17T05:31:13.936800+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Lifecore Biomedical approves CY 2025 transition bonus plan; CEO target 100% of base salary

## Summary
- New bonus plan covers the approximate seven-month transition period May 26, 2025 through Dec 31, 2025.
- Bonus weighted 80% on Adjusted EBITDA and total revenue, 10% on individual objectives, 10% on company goals.
- Target bonus as % of transition-period base salary: CEO Paul Josephs 100%, CFO Ryan Lake 60%, Chief Legal Tom Salus 50%.
- Maximum payout capped at 200% of target level for financial goals; minimum Adjusted EBITDA threshold applies.
- CY 2025 plan replaces the prior FY 2026 Bonus Plan terminated due to the fiscal year change.

## SEC filing metadata
- accession: 0001005286-25-000133
- form_type: 8-K
- ticker: LFCR
- cik: 0001005286
- company_name: LIFECORE BIOMEDICAL, INC. DE
- filed_at: 2025-09-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.35
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1005286/000100528625000133/0001005286-25-000133-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1005286/000100528625000133/lfcr-20250922.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001005286-25-000133
- JSON: https://secwatch.observer/filing/0001005286-25-000133.json
- Plain text: https://secwatch.observer/filing/0001005286-25-000133.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.